Can a single blood test screen for every cancer? — The real value and pitfalls of tumor-marker screening

[Level 1-2 (Strongest-Strong)] [Medical] [Series: Serious Reads for Mature Adults]

⚠️ Please read before proceeding
This article is for informational and educational purposes only. It is not medical advice, diagnosis, or treatment. Decisions about whether to undergo specific tests, how to interpret results, or what to do next should always be made in consultation with a physician (your primary care doctor or relevant specialist) who knows your age, medical history, family history, and current medications. evidage assumes no responsibility for actions or decisions taken based on this article. Guidelines and recommendations evolve over time — always confirm the latest with a medical professional.

“A single blood test can find any cancer.” “I’ll pay out of pocket to test for everything.” If you’re in your 50s or 60s, you’ve probably had this thought. Many people first consider it after hearing a story like “my boss tested PSA, it was high, biopsy found cancer.” It’s natural to think: “couldn’t we do that for all cancers?”

But the world’s major guidelines (US Preventive Services Task Force, Japan’s National Cancer Center, and others) are explicitly skeptical of the “let’s just test everything” approach. This article summarizes the scientific reasoning and how to think about it in general terms.

💡 Bottom line first (as a general principle)
Routine “just-in-case” multi-tumor-marker panels in asymptomatic, healthy adults are not recommended by major guidelines. The reasons: too many false positives, real risk of overdiagnosis, and absence of mortality-reduction evidence. PSA (prostate), AFP (in high-risk groups for liver cancer), and pepsinogen (Japan-specific gastric cancer risk stratification) are limited exceptions. The recommended population screening tests are different: fecal occult blood, mammography, gastric endoscopy, etc.

1. Why “test everything just in case” is counterintuitive but problematic

The statistical “numbers game”

Consider CEA, often used for colorectal cancer. Approximate figures:

• CEA elevation in colorectal cancer patients: 30–40% in early stage, 60–90% in advanced stage (= low sensitivity)
• Many non-cancer causes of elevation: smoking, cirrhosis, diabetes, aging, chronic inflammation, benign polyps, ulcerative colitis

If 10,000 healthy 50-year-old men get CEA testing (hypothetical):

• About 600 will test “positive” (above threshold)
• Of those, perhaps 30–50 actually have colorectal cancer
• The other 550+ are “false positives”

Those 550 will now worry about cancer and undergo additional colonoscopy, CT, MRI, etc. In that process:

• Most learn “no abnormality” — but the psychological toll is real
• A small fraction experience colonoscopy complications (perforation, bleeding: ~1 in 1,000)
• Some will have tiny benign polyps removed “just in case”

Overdiagnosis — a more serious problem

The body harbors many cancers that grow so slowly they cause no symptoms during a person’s lifetime and never become the cause of death.

Notable examples:

• Prostate cancer: ~30% of men over 70 have “silent prostate cancer” found at autopsy
• Thyroid cancer: Increasing in women, but many are slow-growing types
• Kidney cancer: Small tumors often warrant observation only

“Finding” these can lead to treating cancers that didn’t need treating, with consequences:

• Prostate cancer: post-surgery/radiation erectile dysfunction (30–90%), urinary incontinence (5–30%)
• Thyroid cancer: lifelong hormone replacement
• Kidney cancer: reduced renal function, long-term implications

The official position of USPSTF and Japan’s National Cancer Center: evidence that early detection via tumor markers extends life exists only in limited situations.

2. Major tumor markers — the reality (general principles)

Only PSA, AFP (high-risk groups), and pepsinogen receive ⚪︎ or △ for screening. Everything else: “there is no evidence that routine testing in healthy individuals provides a meaningful benefit” — the current international consensus.

3. PSA — the half-exception, and its dual nature

Why PSA is a “half-exception”

• A large randomized trial (ERSPC, ~160,000 European men, 13-year follow-up) showed PSA screening reduced prostate cancer mortality by approximately 20%
• However, the same trial also showed: to prevent 1 prostate cancer death, about 781 men needed to be screened, and 27 men were diagnosed with prostate cancer and treated

The key question is how many of those 27 actually needed treatment. Many likely had cancers that would never have caused symptoms (overdiagnosis).

USPSTF 2018 recommendation (still current)

Japan’s National Cancer Center position

“Evidence on mortality reduction is insufficient. Not recommended as a population-based screening program. When offered as an opt-in test, individuals should be properly informed that the effect is unclear and that overdiagnosis is among the harms.”

How to think about “the boss’s example” as a general principle

“PSA was high → biopsy → cancer found” is a real sequence, and the person may have been saved by early treatment. But as a general principle, these questions are carefully considered for every case:

1. Would this cancer have shortened the patient’s life if untreated? — Determined by pathology (Gleason score, etc.)

2. Has QOL been reduced by treatment? — Surgery and radiation complications

3. Could “active surveillance” have been sufficient? — Low-risk cases sometimes need only monitoring

Individual decisions must be discussed with a urologist. This article only summarizes general principles.

4. Insurance coverage and cost reality in Japan (general)

Typically covered by insurance

• When cancer-related symptoms are present (blood in stool, abnormal bleeding, lumps, unexplained weight loss, etc.)
• When already diagnosed with cancer (monitoring response or recurrence)
• In some high-risk groups (e.g., periodic AFP for HBV/HCV carriers)

“Just-in-case” testing in healthy asymptomatic adults → usually fully out-of-pocket

• Offered as options in 人間ドック (Ningen Dock comprehensive health screening) or paid screening
• Roughly ¥1,500–3,000 per marker; multi-marker packages (PSA, CEA, CA19-9, AFP, CA125, SCC) often ¥10,000–20,000

Japan-specific

• Gastric ABC screening (pepsinogen + H. pylori antibody): risk stratification for gastric cancer; some municipalities subsidize
• Difference between population-based vs opt-in screening: municipal population-based screening selects items based on evidence; opt-in dock options vary widely in evidence quality

Coverage depends on the institution, symptoms, and history. Always confirm with the medical facility.

5. Status of recently discussed new tests

A. Galleri (GRAIL, USA — MCED blood test)

• Claims to detect “signals” from about 50 cancer types in a single blood draw
• Analyzes methylation patterns of cell-free DNA
• Manufacturer-reported false positive rate 0.4%; specificity 99.5%
• However, early-stage sensitivity is limited: ~20–30% overall for Stage I
• Positive predictive value (proportion of positives that are actual cancer): ~62%
• Out-of-pocket in the US (~$950). Not approved or available in Japan.
• PATHFINDER 2 interim data (2025, ~25,000 participants) is supportive, but a large RCT showing mortality reduction is still pending (NHS-Galleri trial)

Current general assessment: promising future, but decisive evidence that “using this leads to longer life” is not yet established.

B. N-NOSE (HIROTSU Bio Science, Japan — nematode cancer test)

• A drop of urine is exposed to nematodes (C. elegans), and their reaction is measured
• Claims “23 cancer types covered,” “easy at home”
• ~¥10,000–20,000 per test
• In October 2023, the PET Cancer Screening Working Group of the Japan Society of Nuclear Medicine launched a formal investigation into accuracy concerns, per reporting
• The vendor itself states it is a “risk assessment, not a diagnosis“
• As of June 2026, independent verification of mortality-reduction benefit is not established

Current general assessment: high media profile but limited third-party verified evidence. “Using this instead of endoscopy or fecal occult blood testing” is not a use pattern endorsed by most specialists.

6. Population screening with proven mortality reduction (Japan’s National Cancer Center, reference info)

The following is general information about current Japanese guidelines, not individualized recommendations:

Optimal screening differs by age, family history, history, smoking, etc. Always consult with your primary care doctor.

7. If you fall into a high-risk group (general principles)

If you fall into the following categories, individualized assessment by a specialist is generally recommended in addition to the population screening above:

• HBV/HCV carriers, cirrhosis: periodic AFP + abdominal ultrasound
• FAP, Lynch syndrome (hereditary colorectal cancer): early-onset colonoscopy
• BRCA1/2 mutation carriers (women): breast MRI + CA125
• Heavy smokers (50+, 20+ pack-years): low-dose lung CT (USPSTF-recommended in the US; available at some Japanese institutions)
• Multiple family history of cancer: individualized evaluation including genetic counseling

If you may fall into these groups, consult a specialist.

8. What is generally not recommended (per major guidelines)

According to major guidelines, the following are considered “evidence insufficient, or harms may exceed benefits” for healthy asymptomatic adults:

• Multi-tumor-marker panels (CEA, CA19-9, CA125, SCC, etc. as a set) “just in case”
• N-NOSE as a standalone cancer screening (as a replacement for proven tests)
• Early adoption of unapproved or evidence-unestablished MCED blood tests like Galleri
• Whole-body PET-CT screening (radiation exposure and false-positive issues; not recommended as population screening)

This is not an absolute rejection. Individualized circumstances may make some of these appropriate under physician judgment. Final decisions should be made in consultation with a physician.

9. evidage’s 4-axis scoring

In the 4-axis weighted scoring, “Guideline-aligned population cancer screening (FOB, mammography, endoscopy, etc.)“:

→ High score. In contrast, “out-of-pocket multi-marker panels” score much lower on effect size and evidence certainty, with high cost, dropping the total substantially.

10. Summary — how to think about this as a general principle

• “Just-in-case blood testing for every cancer” is intuitively appealing but currently not recommended by guidelines in most situations
• The reasons: high false-positive rates, real risk of overdiagnosis, lack of mortality-reduction evidence
• PSA, AFP in high-risk groups, and pepsinogen are partial exceptions
• Population screening (FOB, gastric endoscopy, mammography, cervical cytology, chest X-ray) recommended by Japan’s National Cancer Center constitutes the test set with proven mortality reduction
• Galleri, N-NOSE, and other new tests have potential but “using them to replace conventional screening” lacks evidence at present
• Final decisions must always be made in consultation with a physician familiar with your individual situation

⚠️⚠️⚠️ Important disclaimer (re-emphasized)

This article is for information and education only and is not medical advice, diagnosis, or treatment.

• Decisions about test selection, result interpretation, and additional workup/treatment must be made with a physician who knows your age, history, family history, and medications
• Guidelines and recommendations evolve. Always confirm current information with a medical facility
• Cited trial data, percentages, and recommendation grades are general tendencies and may not apply to any individual
• Evaluations of out-of-pocket and new tests also depend on personal values (early-detection-focused vs QOL-focused vs anxiety management). This article only helps frame those judgments
• evidage assumes no responsibility for actions or decisions made based on this article

If you or a family member have concerning symptoms (blood in stool, abnormal bleeding, lumps, unexplained weight loss, persistent cough, etc.), see a medical professional promptly regardless of this article’s content.

📚 Related pages

• Evaluation Method — evidage’s 4-axis weighted scoring framework
• Evidence Basics
• Independence Policy
• Monthly Top 10

References (key citations)

International evidence and recommendations:

• USPSTF: Prostate Cancer Screening Recommendation (2018, Grade C/D)
• USPSTF: Overdiagnosis in Prostate Cancer Screening Decision (Contextual Review)
• AAFP: Serum Tumor Markers (American Family Physician)
• Schroder FH et al., *NEJM* 2014; “Screening and Prostate Cancer Mortality: ERSPC after 13 years”

Japan guidelines:

• Japan National Cancer Center, Cancer Information Service: “About cancer screening”
• Japan National Cancer Center: “PSA screening guideline for prostate cancer”
• Japan National Cancer Center: “Effectiveness-based colorectal cancer screening guidelines 2024 edition”
• Japan National Cancer Center: “What is a tumor marker test”

New tests:

• GRAIL: Galleri MCED Test Performance Data
• Neal RD et al., *The Lancet* 2023; “GRAIL-Galleri: why the special treatment?”
• PATHFINDER 2 interim results (2025)
• CareNet, October 2023: “N-NOSE accuracy concerns; Japan Society of Nuclear Medicine begins investigation”

Please verify citations and links at the official sites of medical institutions, universities, and public agencies. Figures in this article are as of June 2026.